Healthcare › Medical Devices
Abbott Laboratories
- Ticker
- ABT
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Devices
Price data arrives in a later stage, so no price is shown yet.
Latest news
ImportantABT
Explain this story: Abbott Labs launches blood test to screen for colorectal cancer
Abbott Laboratories' Madison-based cancer diagnostics business has launched a new blood-based colorectal cancer screening test called SimpleScreen CRC. This new test aims to provide an alternative screening option for the estimated 60 million Americans who are overdue for colon screenings, especially for those who decline or do not complete traditional stool-based tests or colonoscopies. While traditional methods remain preferred by the American Cancer Society, this blood test offers a convenient option to detect colorectal cancer and precancerous growths at earlier, more treatable stages.
OtherWisconsin State JournalSector and industry: HealthcareMedical DevicesTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Abbott Laboratories' Madison-based cancer diagnostics business has launched a new blood-based colorectal cancer screening test called SimpleScreen CRC. This new test aims to provide an alternative screening option for the estimated 60 million Americans who are overdue for colon screenings, especially for those who decline or do not complete traditional stool-based tests or colonoscopies. While traditional methods remain preferred by the American Cancer Society, this blood test offers a convenient option to detect colorectal cancer and precancerous growths at earlier, more treatable stages.
ImportantABT
Explain this story: Abbott Laboratories stock trades at EUR 88.71 versus EUR 88.77, minus 0.07 percent
Abbott Laboratories stock was trading at EUR 88.71, down 0.07 percent from its prior close of EUR 88.77 on September 29, 2026. The company reported a 13.0 percent increase in Q2 revenue to USD 12.593 billion and adjusted EPS of USD 1.31. Abbott also raised its full-year 2026 adjusted EPS guidance and saw strong growth in its Medical Devices segment.
OtherAD HOC NEWSHealthcare
ImportantABT
Explain this story: Form 4 Abbott Laboratories For: 29 September By Investing.com
This article announces the filing of a Form 4 for Abbott Laboratories on September 29. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by company insiders. The filing date is confirmed as September 29, 2026, and is accompanied by an Investing.com attribution.
OtherInvesting.com Canada
Company newsMDT
Explain this story: Medtronic reveals cardiac mapping and ablation software clearances
Medtronic announced it has received regulatory clearances for new cardiac mapping and ablation software in both the U.S. and Europe. The clearances are for its Affera Prism-2 Mapping Software and a CE mark for the PulseSelect ProxBox Adapter with Proximity Indicator software, aiming to enhance the company's position in the competitive pulsed field ablation market. These software advancements are designed to provide physicians with better visualization and real-time feedback during cardiac ablation procedures.
OtherMedTech DiveHealthcare
Elsewhere
These links open other websites. We do not provide price data yet.